Arcadia Biosciences Inc. announced the immediate exercise of certain outstanding preferred investment options, allowing the purchase of up to 808,595 shares of common stock at a reduced exercise price of $2.575 per share, down from the original $9.00 per share. The company expects to receive approximately $2.1 million in gross proceeds from this transaction, before deducting placement agent fees and offering expenses. In connection with this exercise, Arcadia will also issue new unregistered preferred investment options to purchase up to 1,617,190 shares of common stock at an exercise price of $2.325 per share. These new options are immediately exercisable and will expire thirty months after the effective date of a forthcoming resale registration statement. Net proceeds will be used for working capital and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcadia Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623496-en) on January 12, 2026, and is solely responsible for the information contained therein.